Thank you for giving me the opportunity to review this manuscript dealing with a subject of high interest to me I appreciate the approach diffracted on both leading regulators (EMA and FDA) and also the great timespan of the study I realize it represents a great deal of work and also appreciate the body of data that are submitted, notably in additional material The manuscript contains lots of findings and it was quite difficult to me to retrieve the most important messages to be extracted from this work. In this regard, the first paragraph of the Discussion is welcome Background The references illustrating the 1st statement (and sentence) could be updated. For instance, a recent paper was published by FDA officials about drug regulation in the US [Gassman AL, NEJM 2017] . I think that two recent references have been missed by the authors and should be cited at some point of time in the manuscript : AV Morant, Clinical Pharmacology & Therapeutics 2018, studying drugs approved by the EMA upon the basis of a single pivotal trial; and Djulbegovic B, J Clin Epidemiol 2018, lager effect sizes in nonrandomized studies… about nonrandomized evidence Methods I would expect the authors to justify their choice to retain solely drugs approved in some areas. Is it because they believe that those areas are more prone to approvals based upon limited evidence? Or just because they have been over the last decade a high focus of pharmaceutical innovation? Page 4 of the pdf, second paragraph, could the authors justify at this stage why they also (which is a little unusual to my knowledge) selected drugs that were not approved or withdrawn? Maybe I misunderstand something but it seems to me that there is a misalignment between the claim of the authors in the last paragraph of the Intro and the methods used to search drugs. In the Intro, they state that they are to study drugs approved upon non-randomized data. However, I observe that in the Methods, they select drugs according to their non-conventional regulatory pathway. It seems that this is not exactly the same thing even though I recognize that there should be a substantial overlap, I'm not sure that this is always the case (that on one side, all non-randomized evidence goes into non-conventional pathways and that on one side, all nonconventional pathways are constructed through non-randomized data) 4th paragraph, the two independent reviewers involved at this stage should be indicated (initials between brackets). Ditto in the following paragraph and the mention made to "one researcher" and a "second researcher" I'm not an expert of non-randomized evidence and I'd be interested to know whether the categorization made by the authors into 3 types of external controls has already been used and (or) validated. A reference might help to make more robust this classification (that I do not dispute per se). Results 1st sentence: it is unclear to me whether "all therapy areas" refers to all areas that have been preselected by the authors as their topics of study or to all therapeutic areas in total Lines 148-149, the authors should give the mean number of studies per approved product (even if it is obvious to calculate) Line 243 (1st paragraph of the Discussion), could the authors be more explicit about the "high unmet need"? Did they measure it or is it based upon statements from the EMA for instance? Line 249, there is a typo error ("the" and not "he). Moreover, the increase in nonrandomized submissions over the study period could be further commented by the authors. Is it likely to be linked to a trend affecting accepted evidence or related to the increase in hematologic drugs approved over that period of time? Line 263, there might be a grammatical error ("are" instead of "is"?)
REVIEWER
Nadia Sourial McGill University, Canada REVIEW RETURNED 10-Aug-2018
GENERAL COMMENTS
This manuscript provides a meaningful and important contribution to the literature on the use of non-randomized studies for the regulatory approval of orphan and rare drugs. The paper is well-written, thorough and methodologically sound. However, a few aspects of the study require further clarification or justification:
-Only submissions with an indication for hematological cancer, condition related to stem cell transplantation, other (non-malignant) hematologic condition or rare metabolic disease were considered eligible for the systematic review. While no justification is given in the methods section, it is mentioned in the discussion that the scope of the search was limited to products with pre-specified designations. Please clarify whether the list of indications selected corresponds to an exhaustive list of products with pre-specified designations or whether they represent a subset of a larger list of such products. If the latter, please provide a justification for this selection.
-Several units of analysis are discussed in this manuscript including the number of studies, submissions, indications and products and it is hard to follow when the unit of analysis changes from sentence to sentence (e.g. p.4 lines 142-155). Please provide a sentence towards the beginning of the results clearly linking the different units of analysis and how many in each case. It would also help for each paragraph to refer to only one type.
-What was the level of agreement between the two reviewers? Was inter-rater reliability assessed? -For Figure 2 , the order of categories is difficult to follow and compare. Please put categories in decreasing order of frequency instead of alphabetical. The use of colors is also not clear.
-The authors discuss the result that only the three most recent submissions used external controls based on individual-level data and proper use matching, stratification, or re-weighting techniques. That most of the accepted submissions are based on lower quality non-randomized designs and analytical techniques should be emphasized in the discussion and in the conclusion as a concern regarding the validity of the efficacy of these products. The use of techniques such as propensity-score matching and inverse probability weighting, assuming all confounders are known and included, provide the highest level of evidence for a causal effect using observational data. While it may be the only recourse available, the use of aggregate or historical external controls exposes any estimation of effect to selection and confounding bias. These concerns should be clearly stated.
-I did not see any information regarding whether the review protocol was registered in the Cochrane database or PROSPERO.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 Background -The references illustrating the 1st statement (and sentence) could be updated. For instance, a recent paper was published by FDA officials about drug regulation in the US [Gassman AL, NEJM 2017].
We have added the reference as suggested.
-I think that two recent references have been missed by the authors and should be cited at some point of time in the manuscript : AV Morant, Clinical Pharmacology & Therapeutics 2018, studying drugs approved by the EMA upon the basis of a single pivotal trial; and Djulbegovic B, J Clin Epidemiol 2018, lager effect sizes in nonrandomized studies… about nonrandomized evidence We thank the reviewer for pointing us to these two publications. We have added both reference to the introduction. Additionally, we have added the study by Djulbegovic et al. to our discussion on effect sizes (end of 3rd paragraph of discussion).
Methods -I would expect the authors to justify their choice to retain solely drugs approved in some areas. Is it because they believe that those areas are more prone to approvals based upon limited evidence? Or just because they have been over the last decade a high focus of pharmaceutical innovation?
We reviewed all submissions in the non-conventional pathways, but only extracted data from the submissions related to indications that fell within our sphere of interest as described in the criteria below, and these formed the focus of our study. The rationale for the selection of indications was to focus the scope of the review, and were selected as follows:
• Oncology has been consistently reported as the most common indication for approvals in absence of good quality RCTs, with haematologic cancers being more common than solid tumour cancers. Therefore, we focused our review on haematologic cancers, extending it to include two other bloodrelated indications: conditions involving stem cell transplant, and other haematologic conditions.
• Outside of cancer, rare metabolic diseases have been reported as the next most common type of indication associated with non-RCT evidence, and thus were included in our review.
We have added brief clarification in the first paragraph of the methods section, and also added a reference to further support the choice.
-Page 4 of the pdf, second paragraph, could the authors justify at this stage why they also (which is a little unusual to my knowledge) selected drugs that were not approved or withdrawn?
We included submissions that used non-randomized data, but were not approved or were withdrawn, in order to provide a comparison to the approved submissions that used non-randomized evidence. For example, this allowed us to see comments from the EMA committee related to why they found a specific non-randomized design unconvincing, and showed differences in how the two agencies viewed the evidence presented.
Maybe I misunderstand something but it seems to me that there is a misalignment between the claim of the authors in the last paragraph of the Intro and the methods used to search drugs. In the Intro, they state that they are to study drugs approved upon non-randomized data. However, I observe that in the Methods, they select drugs according to their non-conventional regulatory pathway. It seems that this is not exactly the same thing even though I recognize that there should be a substantial overlap, I'm not sure that this is always the case (that on one side, all non-randomized evidence goes into non-conventional pathways and that on one side, all non-conventional pathways are constructed through non-randomized data)
We agree with the reviewer that these are not the same thing. Our sampling frame (i.e. lists of all products with conditional approval, exceptional circumstances, or orphan medicine designation from the EMA, or orphan drug status, accelerated approval, breakthrough therapy, fast track, or priority approval by the FDA) represents a subset of all regulatory submissions.
We have acknowledged this aspect of our study design in the limitations section of the discussion (from original submission, second to last paragraph of discussion section, third point ["Third, our search, while systematic in nature, was not an exhaustive search of all submissions to FDA and EMA…]). We described that when we cross-referenced our list of included products with those identified by Hatswell et al (who had reviewed every single submission to the EMA and FDA), our strategy yielded a comprehensive set of products within the pre-specified indications of interest and the timeframe of our review. This was irrespective of whether the product was reviewed through a non-conventional pathway, suggesting that the majority (but not all) of non-randomized evidence is submitted via non-conventional pathways.
-4th paragraph, the two independent reviewers involved at this stage should be indicated (initials between brackets). Ditto in the following paragraph and the mention made to "one researcher" and a "second researcher" We have added the initials.
-I'm not an expert of non-randomized evidence and I'd be interested to know whether the categorization made by the authors into 3 types of external controls has already been used and (or) validated. A reference might help to make more robust this classification (that I do not dispute per se).
We did not use a specific published classification, but developed our own for this review. Our typology of non-randomised studies broadly aligns with other classification schemes used in the literature, which consider non-randomised studies to be either "historically controlled" or "uncontrolled". There are two main differences between our classification and this more broad definition.
-First, our classification subdivides studies more broadly classed as "historical controls" into subtypes by methodology of comparison (i.e. individual patient data versus. aggregate-level data comparisons).
-Second, our classification applies a different name ("undefined external controls") to studies that are more conventionally called "uncontrolled", as our manuscript focuses on characterizing external control groups. We added the word 'undefined' to the term "external controls" for clarification, as there are no defined control used in studies that fall into this class. However, studies with undefined external controls rely on an unreferenced body of literature or general medical knowledge that contextualized the findings presented in the submission for the reviewers. In addition, the term "undefined" matches terminology used in the ICH harmonised tripartite guideline (E10) on the choice of control group and related issues in clinical trials.
Results -1st sentence: it is unclear to me whether "all therapy areas" refers to all areas that have been preselected by the authors as their topics of study or to all therapeutic areas in total The sentence has been edited for clarity.
-Lines 148-149, the authors should give the mean number of studies per approved product (even if it is obvious to calculate) The mean number of studies has been added.
-Line 243 (1st paragraph of the Discussion), could the authors be more explicit about the "high unmet need"? Did they measure it or is it based upon statements from the EMA for instance?
We have clarified the text to indicate that we are referring to an unmet need with regards to treatment availability, i.e. a lack or scarcity of available treatments.
-Line 249, there is a typo error ("the" and not "he).
We have corrected the typo.
-Moreover, the increase in nonrandomized submissions over the study period could be further commented by the authors. Is it likely to be linked to a trend affecting accepted evidence or related to the increase in hematologic drugs approved over that period of time?
We feel that while the increase in submissions based on non-randomized evidence is a very interesting phenomenon, it is not within the scope of our study, which already presents and discusses many results. We have therefore not added a detailed discussion of this item.
Line 263, there might be a grammatical error ("are" instead of "is"?) This error has been corrected.
Reviewer: 2 -Only submissions with an indication for hematological cancer, condition related to stem cell transplantation, other (non-malignant) hematologic condition or rare metabolic disease were considered eligible for the systematic review. While no justification is given in the methods section, it is mentioned in the discussion that the scope of the search was limited to products with pre-specified designations. Please clarify whether the list of indications selected corresponds to an exhaustive list of products with pre-specified designations or whether they represent a subset of a larger list of such products. If the latter, please provide a justification for this selection.
We refer the reviewer to our response to Reviewer 1's questions on a similar topic. (See answers to reviewer 1, first question under "Methods")
We thank the reviewer for highlighting this. We have responded by adding a clarifying sentence in the method section (last paragraph of methods section), by checking the manuscript text for areas of potential confusion and by streamlining the use of the units throughout the manuscript.
-What was the level of agreement between the two reviewers? Was inter-rater reliability assessed? We did not systematically assess the proportion of studies for which the reviewers agreed on eligibility for all reviewed submissions. However, any discrepancies that did appear could be discussed and resolved by consensus between the two reviewers.
-For Figure 2 , the order of categories is difficult to follow and compare. Please put categories in decreasing order of frequency instead of alphabetical. The use of colors is also not clear. The figure has been re-structured as suggested.
-The authors discuss the result that only the three most recent submissions used external controls based on individual-level data and proper use matching, stratification, or re-weighting techniques. That most of the accepted submissions are based on lower quality non-randomized designs and analytical techniques should be emphasized in the discussion and in the conclusion as a concern regarding the validity of the efficacy of these products. The use of techniques such as propensityscore matching and inverse probability weighting, assuming all confounders are known and included, provide the highest level of evidence for a causal effect using observational data. While it may be the only recourse available, the use of aggregate or historical external controls exposes any estimation of effect to selection and confounding bias. These concerns should be clearly stated.
We have expanded the discussion on this point while taking into account that an optimal study design may not always be possible (fifth paragraph of discussion: "In the absence of head-to-head…; sixth paragraph of the discussion: "Among our three pre-defined types…"). Our experience tells us that data availability for external controls can be limited, and that the study design must therefore be chosen within the options available.
-I did not see any information regarding whether the review protocol was registered in the Cochrane database or PROSPERO. The protocol was not registered. 
GENERAL COMMENTS
The comments from the primary review have been adequately addressed.
Thanks again for giving me the opportunity to review this paper dealing with an interesting subject.
REVIEWER

Nadia Sourial McGill University
REVIEW RETURNED
12-Oct-2018
GENERAL COMMENTS
The authors' revisions to their manuscript adequately address the comments and concerns that were raised during the first review. One final comment is that the authors should include the absence of a formal inter-rater reliability assessment in their study limitations. Provided this change, I would agree for this manuscript to be published in its current form. Thank you for the opportunity to review this work.
